ascopubs.org

BCR-ABL kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the second-generation TKI era.

Clinical trial and compassionate use experience with glucarpidase for methotrexate toxicity. This is an ASCO Meeting Abstract from the 2012 ASCO Annual Meeting I. This abstract does not include a full ...
Medscape

Abl Tyrosine Kinase Inhibitors for Overriding Bcr-Abl/T315I: From the Second to Third Generation

Expert Rev Anticancer Ther. 2008;8(9):1387-1398. Expert Rev Anticancer Ther. 2008;8(9):1387-1398. © 2008 Expert Reviews Ltd. No writing assistance was utilized in ...
BioWorld

Chinese scientists describe new Bcr-Abl kinase inhibitors

Beijing Infinite Intelligence Pharmaceutical Technology Co. Ltd. and Suzhou Fish-Summoning Biotechnology Co. Ltd. have identified compounds acting as Bcr-Abl (Bcr-Abl1) kinase inhibitors reported to ...
ascopubs.org

Treatment of patients (pts) with chronic myeloid leukemia (CML) and imatinib failure after developing BCR-ABL kinase mutations with allogeneic stem cell transplantation (ASCT)

Outcome of salvage therapy for relapsed or refractory peripheral T-cell lymphoma (PTCL), anaplastic large cell lymphoma (ALCL), and diffuse large B-cell lymphoma (DLBCL) No significant financial ...
Medical Xpress

Digital PCR identifies leukemia patients who can stop drug treatment

Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...